ProFibrix (Netherlands) a clinical-stage company focused on fibrinogen for use in homeostasis and regenerative medicine, closed a $11M Series B financing. Participants include Gilde Healthcare Partners and Index Ventures.
LifeBond (Israel) a commercial-stage developer of wound-closure and hemostasis biomaterials, closed a $8M Series B financing. Participants include Pitango Venture Capital, GlenRock Israel and The Zitelman Group.